Thomas Soloway
Director/Board Member bei THIRD HARMONIC BIO, INC.
Vermögen: - $ am 31.03.2024
Profil
Thomas M.
Soloway was the founder of Transcept Pharma, Inc. founded in 2002, where he held the title of SVP, Chief Operating & Financial Officer from 2012 to 2013.
He is currently the Chief Executive Officer at T-Knife GmbH since 2021 and also holds the same title at T-Knife Therapeutics, Inc. He is an Independent Director at Third Harmonic Bio, Inc. since 2022.
Mr. Soloway received his undergraduate degree from the University of Southern California and his MBA from Georgetown University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
THIRD HARMONIC BIO, INC.
-.--% | 06.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Thomas Soloway
Unternehmen | Position | Beginn |
---|---|---|
THIRD HARMONIC BIO, INC. | Director/Board Member | 01.07.2022 |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Chief Executive Officer | 19.01.2021 |
T-Knife Therapeutics, Inc. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Thomas Soloway
Unternehmen | Position | Ende |
---|---|---|
SATSUMA PHARMACEUTICALS, INC. | Director/Board Member | 08.06.2023 |
ASCENDIS PHARMA A/S | Director of Finance/CFO | 01.09.2015 |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Founder | 01.12.2013 |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Board Member | 06.02.2009 |
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Corporate Officer/Principal | - |
Ausbildung von Thomas Soloway
University of Southern California | Undergraduate Degree |
Georgetown University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ASCENDIS PHARMA A/S | Health Technology |
PARATEK PHARMACEUTICALS, INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Finance |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
T-Knife Therapeutics, Inc. |